Physician profile
Jonathan Dau
NPI 1467809608
$42,077.17
in general payments reported to CMS, 2019-2025
27 companies · $8,657 in 2025
The $8,657 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2021: $897 · 2022: $12K · 2023: $15K · 2024: $5,361 · 2025: $8,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $12K · Travel and Lodging: $3,626 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,793.11 |
| Consulting Fee | $12,142.50 |
| Travel and Lodging | $3,625.94 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $7,301.85 | 2021-2025 | Tremfya, Stelara |
| Glaxosmithkline, LLC. | $6,791.91 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $6,405.54 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $4,175.46 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $3,892.25 | 2022-2025 | |
| Abbvie INC. | $3,587.32 | 2021-2025 | Rinvoq, Humira |
| Amgen INC. | $2,927.28 | 2021-2025 | Tavneos, Uplizna, Enbrel |
| Sobi, INC | $2,481.00 | 2022-2025 | |
| Ucb, INC. | $1,187.11 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $649.53 | 2022-2025 | Taltz, Zepbound |
| Pfizer INC. | $554.68 | 2021-2025 | |
| Genentech, INC. | $344.90 | 2022-2025 | Gazyva, Actemra |
| Aurinia Pharma U.S., INC. | $323.51 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $271.89 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $266.29 | 2021-2025 | Orencia, Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $207.96 | 2021-2024 | Tymlos |
| Horizon Therapeutics Plc | $157.35 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $117.87 | 2022-2025 | Actemra, Gazyva, Rituxan |
| Merck Sharp & Dohme LLC | $93.94 | 2025 | |
| Fresenius Kabi USA, LLC | $78.69 | 2023-2025 | Idacio |
| Novo Nordisk INC | $75.87 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Sandoz INC. | $54.82 | 2023 | Hyrimoz |
| Bioventus LLC | $41.82 | 2023 | Durolane, Gelsyn-3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.98 | 2024-2025 | Ofev |
| Mylan Institutional INC. | $20.55 | 2023 | |
| Alvogen INC | $20.13 | 2023 | Teriparatide |
| Invivyd INC | $17.67 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.